BRAF and melanoma: This clinical tumor sample was obtained from a patient with BRAF V600-mutated melanoma who was treated with BRAF and MEK inhibitors and developed a metastatic lesion with acquired resistance coincident with the acquisition of ecDNA (Fig. 2a).